ArticleFrontiers in immunology2026
Development and validation of a potency assay matrix for optimized and consistent manufacture of clinical mesenchymal stem/stromal cells.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mesenchymal stem/stromal cells (MSCs) are being evaluated as cell-based therapies for inflammatory and immune-mediated disorders. However, variability in clinical efficacy and a lack of validated potency assays have impeded regulatory approval for commercialization. Here, we report on our success with developing a matrix of potency assays for evaluating the therapeutic fitness of bone marrow-derived MSCs and demonstrate that the cells consistently suppress T cell proliferation, induce regulatory T cell differentiation, and polarize monocytes into anti-inflammatory M2 macrophages. Methods: Vertebrae were recovered from consented and screened organ donors by Organ Procurement Organizations and shipped on ice to a central processing facility for isolation of vertebral body bone marrow. MSCs were cultured in a xenogeneic-free medium and characterized based on established markers and expanded for 4 passages. Modulation of immune cells isolated from peripheral blood was evaluated using T cell suppression assays, macrophage polarization, regulatory T cell (Treg) induction and monocyte/macrophage chemoattraction assays. Results: Mechanistic studies revealed that potency is mediated by MSC-secreted immunoregulatory molecules, including macrophage colony-stimulating factor (M-CSF), transforming growth factor-β1 (TGFβ1), and the chemokine CCL2, as well as by tryptophan depletion via the cytoplasmic protein indoleamine 3,4 dioxygenase-1 (IDO1). Additionally, we show that MSCs secrete high levels of extracellular vesicles which potently induce an anti-inflammatory phenotype in T cells and monocytes. These findings were employed to develop a matrix of surrogate potency assays which consistently demonstrated predicted Discussion: This potency assay platform provides a critical tool for ensuring the quality and consistency of MSC products and will facilitate clinical translation by demonstrating comparability between MSC donors as well as manufactured lots and potentially predicting therapeutic efficacy in clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.